Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
All content curated by
Published in Oncology

Journal Scan / Research · March 03, 2023

Type of Adjuvant Endocrine Therapy and Disease-Free Survival in Patients With Early HR+/HER2+ Breast Cancer

NPJ breast cancer

 

Additional Info

NPJ breast cancer
Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial
NPJ Breast Cancer 2023 Feb 04;9(1)6, MV Dieci, G Bisagni, S Bartolini, A Frassoldati, R Vicini, S Balduzzi, R D'amico, P Conte, V Guarneri

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading